Lung adenocarcinoma harboring rare epidermal growth factor receptor L858R and V834L mutations treated with icotinib:A case report  

作　　者：Shu-Sen Zhai Hui Yu Tian-Tian Gu Yan-Xia Li Yan Lei Hai-Yan Zhang Tong-Huan Zhen Yun-Ge Gao 

机构地区：[1]Oncology Section,PLA Strategic Support Force Characteristic Medical Center,Beijing 100101,China [2]Cancer Research Institute,YuceBio,Shenzhen 518000,Guangdong Province,China

出　　处：《World Journal of Clinical Cases》2020年第17期3841-3846,共6页世界临床病例杂志

摘　　要：BACKGROUND Epidermal growth factor receptor(EGFR)tyrosine-kinase inhibitors are widely used for the treatment of non-small-cell lung cancer with EGFR mutations.However,patients with rare,even compound EGFR mutations have different responses to EGFR-tyrosine-kinase inhibitors,which bring uncertainty to clinical treatment.CASE SUMMARY A 45-year-old female patient presented with a 3-mo history of cough and white sputum without chest pain.Chest computed tomography revealed lung spaceoccupying lesions and multiple lymphadenectasis.Bronchoscopy and pathology suggested lung adenocarcinoma.Compound variation of EGFR gene(exon 21 L858 R/V834 L)was detected in both tissue and circulating tumor deoxyribonucleic acid samples.As a result of next-generation sequencing and her family’s wishes,the patient was given oral treatment with icotinib hydrochloride(125 mg/d,tid)from March 21,2019 and has achieved stable disease for the last 1 year.CONCLUSION Non-small cell lung adenocarcinoma with EGFR L858 R/V834 L was treated successfully with icotinib,and it may be a new medication treatment option.

关 键 词：Icotinib hydrochloride Epidermal growth factor receptor L858R/V834L Nonsmall cell lung cancer Stable disease Case report 

分 类 号：R734.2[医药卫生—肿瘤]